Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient StoryRead more →

Stage 1 lung adenocarcinoma: NED after surgery alone

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: MET exon 14 skipping; PIK3CA p.; KRAS exon 2 p./D

Both independent early-stage lung adenocarcinomas were resected without lymph-node metastasis; follow-up showed normalized oncologic markers, negative lung-cancer autoantibodies, improved HRCT findings, and no recurrence for 1 year.

PubMed CentralRead more →

BRAF-mutant lung cancer: complete pathologic response after targeted therapy and surgery

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: BRAF ; PD-L1 80%; TMB 1 mutation per megabase; MSS

Pathologic complete response after BRAF/MEK-targeted neoadjuvant therapy and surgery for BRAF V600E lung cancer; no recurrence or metastasis observed as of March 2024.

PubMed CentralRead more →

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD AndersonRead more →

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed CentralRead more →

Stage III lung squamous cell cancer treated with immunotherapy, surgery and chemotherapy

Patient Info: Anonymized, male, 50s | Stage III

After surgery and systemic treatment, updated follow-up found no recurrence or metastasis. Tislelizumab remained stopped after recurrent adrenal insufficiency.

PubMed CentralRead more →

Guillain-Barré syndrome after surgery for Stage II lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage II

No lung-cancer recurrence was seen at follow-up after complete resection. His postoperative Guillain-Barré syndrome resolved within 3 months after immunoglobulin treatment and rehabilitation.

PubMed CentralRead more →

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

RET-fusion lung adenocarcinoma responding to pralsetinib and bevacizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KIF13A-RET fusion

Metastatic Site: pleura

He had 27 months of disease-free survival on pralsetinib before pleural and nodal recurrence. After bevacizumab was added, imaging showed reduction of the pleural lesion and mediastinal nodes and circulating tumor DNA became undetectable in December 2023.

PubMed CentralRead more →

Stage IIIA EGFR-mutated lung squamous cell carcinoma: pathologic complete response to aumolertinib

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: EGFR exon 19 deletion; p40-positive lung squamous cell carcinoma

At the 1 April 2024 cutoff, she had no recurrence after 20 months of treatment following neoadjuvant aumolertinib, pathologic complete response at surgery, and ongoing adjuvant aumolertinib.

PubMed CentralRead more →

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed CentralRead more →

Two early-stage primary lung cancers and bronchopleural fistula closure with VV-ECMO support

Patient Info: Anonymized, Male, 50s | Stage I

As of May 2024, the postoperative bronchopleural fistula had been successfully closed, the residual cavity had closed, and no BPF was seen on 3-month CT; longer cancer recurrence surveillance was not reported.

PubMed CentralRead more →

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed CentralRead more →

Stage II lung adenocarcinoma with a fetal-type component treated with surgery

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: PD-L1 negative; no alterations identified on Oncomine Dx testing

He was doing well without recurrence 8 months after surgery.

PubMed CentralRead more →

Stage III squamous lung cancer with a postoperative bronchopleural fistula that resolved with treatment

Patient Info: Anonymized, male, 60s | Stage III

The postoperative bronchopleural fistula resolved after anti-infective treatment, and serial CT scans showed no lung-cancer recurrence during ongoing follow-up.

PubMed CentralRead more →

Stage III lung adenocarcinoma with a postoperative bronchopleural fistula and no recurrence

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: EGFR, ALK, KRAS, RET and ROS1 negative

After treatment of a postoperative bronchopleural fistula, she was followed for more than 1 year with CT every 3 months and no lung-cancer recurrence.

PubMed CentralRead more →

Stage I lung adenocarcinoma diagnosed alongside follicular lymphoma

Patient Info: Anonymized, male, 60s | Stage I

A 69-year-old man was found to have Stage I lung adenocarcinoma and a separate follicular lymphoma, allowing each cancer to be managed independently.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Tim's Patient Story

Patient Info: Tim Monds, Male, 50s | Stage IV

Biomarkers: High PD-L1 expression

Metastatic Site: Other lung lobes / lung nodules

As of March 2024, Tim Monds was identified as a Stage IV lung cancer survivor involved in discussion of the PaCES early palliative-care project and broader lung cancer advocacy.

Lung cancer brain metastasis grew into a pre-existing meningioma

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: brain

Six months after lung surgery, a pathologically confirmed brain metastasis developed beside and partly infiltrated a pre-existing meningioma. It was surgically removed, and the patient declined radiochemotherapy afterward.

PubMed CentralRead more →

Basaloid squamous lung cancer that regressed and later regrew

Patient Info: Anonymized, male, 70+

A lung nodule nearly disappeared without treatment, then regrew 2 years later and was resected as basaloid squamous cell carcinoma.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient StoryRead more →

Stage III small-cell lung cancer had a complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, female, 50s | Stage III

Surgery showed a pathological complete response, and no recurrence or metastasis was found through 12 months of follow-up.

PubMed CentralRead more →